Houde CA, Khan A, Jacobus SJ, et al. Treatment outcomes and prognostic factors with lenalidomide, bortezomib, and dexamethasone (RVd) alone versus Rvd plus autologous stem cell transplantation (ASCT) in African American (AA) patients (Pts) with newly diagnosed multiple myeloma (NDMM) in the Determination phase 3 trial [abstract]. Blood. 2023;142(suppl 1):4762.

The first author of this American Society of Hematology Annual Meeting abstract, Christiane A. Houde, BS, should not be listed as an author. The first author should be Jeffrey A. Zonder, MD, with Karmanos Cancer Institute, Detroit, MI, as the affiliation. Under “Disclosures,” the first author’s disclosures should read “Zonder:Janssen, Prothena, Regeneron: Consultancy; Bristol-Myers Squibb/Celgene: Research Funding; Takeda, Telios: Other: Consultancy which has ended within the past 24 months.”